smooth muscle actin and s100p on non germinal centre diffuse large b cell lymphoma are adverse prognostic factors pilot study平滑肌肌动蛋白和非s100p生发中心弥漫性大b细胞淋巴瘤是试点研究不良预后因素.pdf

Diagnostic Pathology BioMed Central Research Open Access Smooth muscle actin and s100p on non germinal centre diffuse large B cell lymphoma are adverse prognostic factors: pilot study Howayda Abd El All*1,2 Address: 1Department of Pathology, Faculty of Medicine, Suez Canal University, Ismailiya, Egypt and 2Immunohistochemistry Laboratory, Nasser Institute, MOHP, Cairo, Egypt Email: Howayda Abd El All* - howayda@ * Corresponding author Published: 2 March 2007 Received: 14 January 2007 Accepted: 2 March 2007 Diagnostic Pathology 2007, 2:9 doi:10.1186/1746-1596-2-9 This article is available from: /content/2/1/9 © 2007 Abd El All; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Introduction: The expression of smooth muscle actin (SMA) and s100p has been identified on an aggressive retro-orbital diffuse large B cell lymphoma (DLBCL) [1]. Aim: To assess the prognostic significance of immunohistochemical (IHC) expression of SMA and s100p on DLBCL. Materials and methods: Twenty nine cases diagnosed as DLBCL were first classified into germinal centre (GC) B cell like and non GC origin either activated B cells (ABC) or type 3 based on their immunoreactivity for CD 10, bcl-6 and Mum-1. Bcl-2 and MIB-1 as adverse